Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.
Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Cortellini A, et al. Among authors: grassadonia a. Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020. Oncoimmunology. 2020. PMID: 32002308 Free PMC article.
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
Natoli C, Cianchetti E, Tinari N, Angelucci D, Grassadonia A, Zilli M, Ficorella C, Ricevuto E, Grossi S, De Tursi M, Carella C, Rispoli AI, Iacobelli S. Natoli C, et al. Among authors: grassadonia a. Ann Oncol. 2007 Jun;18(6):1015-20. doi: 10.1093/annonc/mdm076. Epub 2007 Mar 17. Ann Oncol. 2007. PMID: 17369601 Free article. Clinical Trial.
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.
Zilli M, Grassadonia A, Tinari N, Di Giacobbe A, Gildetti S, Giampietro J, Natoli C, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO). Zilli M, et al. Among authors: grassadonia a. Biochim Biophys Acta. 2009 Jan;1795(1):62-81. doi: 10.1016/j.bbcan.2008.08.003. Epub 2008 Aug 29. Biochim Biophys Acta. 2009. PMID: 18804516 Review.
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies.
Tinari N, Lattanzio R, Querzoli P, Natoli C, Grassadonia A, Alberti S, Hubalek M, Reimer D, Nenci I, Bruzzi P, Piantelli M, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO). Tinari N, et al. Among authors: grassadonia a. Int J Cancer. 2009 Jan 15;124(2):333-8. doi: 10.1002/ijc.23970. Int J Cancer. 2009. PMID: 18942707
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.
Angelucci D, Tinari N, Grassadonia A, Cianchetti E, Ausili-Cefaro G, Iezzi L, Zilli M, Grossi S, Ursini LA, Scognamiglio MT, Castrilli G, De Tursi M, Noccioli P, Cioffi P, Iacobelli S, Natoli C. Angelucci D, et al. Among authors: grassadonia a. J Cancer Res Clin Oncol. 2013 Feb;139(2):269-80. doi: 10.1007/s00432-012-1325-9. Epub 2012 Oct 10. J Cancer Res Clin Oncol. 2013. PMID: 23052698 Free PMC article.
Tumor-derived microvesicles: the metastasomes.
Ghasemi R, Grassadonia A, Tinari N, Piccolo E, Natoli C, Tomao F, Iacobelli S. Ghasemi R, et al. Among authors: grassadonia a. Med Hypotheses. 2013 Jan;80(1):75-82. doi: 10.1016/j.mehy.2012.10.011. Epub 2012 Nov 21. Med Hypotheses. 2013. PMID: 23177570
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Natoli C, et al. Among authors: grassadonia a. J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20. J Cancer Res Clin Oncol. 2013. PMID: 23604446 Free PMC article.
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Grassadonia A, Di Nicola M, Grossi S, Noccioli P, Tavoletta S, Politi R, Angelucci D, Marinelli C, Zilli M, Ausili Cefaro G, Tinari N, De Tursi M, Iezzi L, Cioffi P, Iacobelli S, Natoli C, Cianchetti E. Grassadonia A, et al. Ann Surg Oncol. 2014 May;21(5):1575-82. doi: 10.1245/s10434-014-3535-7. Epub 2014 Feb 13. Ann Surg Oncol. 2014. PMID: 24522992 Free PMC article.
98 results